Holding types
Countries
Sectors
Analyst ratings
Market Data
Dividend
Strategic rebranding shows a commitment to neurodegenerative treatments and promoting healthy aging. On September 17, 2024, ANEW MEDICAL, INC. (NASDAQ: WENA) announced its new name and ticker symbol, Klotho Neurosciences, Inc. (NASDAQ: KLTO), along with the launch of its new website, www.klothoneuro.com.
NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The ANEW MEDICAL, INC. Board of Directors.
The company plans to utilize the innovative and patented Klotho Gene (s-KL) in its research. On September 4, 2024, ANEW MEDICAL, INC. (NASDAQ: WENA), a biotechnology firm based in the U.S., revealed its two main objectives for advancing cell and gene therapy.
NEW YORK, September 4, 2024 (GLOBE NEWSWIRE) - ANEW MEDICAL, INC.
On August 26, 2024, ANEW MEDICAL, INC. (NASDAQ: WENA), a top U.S. biotechnology firm focused on cell and gene therapies for aging and related illnesses, reported that investors have successfully converted their convertible promissory notes. This conversion has helped the company eliminate over $4 million in long-term debt.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ: WENA), a top U.S. biotechnology firm focused on developing cell and gene therapies for aging and related illnesses, has announced that investors have successfully converted their convertible promissory notes.
New York, NY. August 21, 2024 – ANEW MEDICAL, INC.
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or the “Company”) (Nasdaq: WENA) has announced that it has signed an exclusive global licensing deal with Transfertech Sherbrooke (“TTS”) for Nanoject, a device that allows for needle-free injection of freeze-dried nanopowder medicines and vaccines.
New York, NY, August 19, 2024 – ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) is a company based in the United States.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA), a U.S. biotechnology firm dedicated to creating cell and gene therapies for aging and related diseases, has announced that Jeffrey LeBlanc has been appointed as the new Chief Financial Officer (CFO). He takes over from Edward Cong Wang, the interim CFO, who previously served as the CFO of Redwoods Acquisition Corp, the company that merged with ANEW.
FAQ
- What is ANEW ETF?
- Does ANEW pay dividends?
- What stocks are in ANEW ETF?
- What is the current assets under management for ANEW?
- What is ANEW average volume?
- What is ANEW expense ratio?
- What is ANEW inception date?